Dapagliflozin BDBM20880 CHEMBL429910 (2S,3R,4R,5S,6R)-2-{4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl}-6-(hydroxymethyl)oxane-3,4,5-triol C-aryl glucoside, 6 BMS-512148
- Li, Z; Xu, X; Deng, L; Liao, R; Liang, R; Zhang, B; Zhang, L Design, synthesis and biological evaluation of nitric oxide releasing derivatives of dapagliflozin as potential anti-diabetic and anti-thrombotic agents. Bioorg Med Chem 26: 3947-3952 (2018)
- Meng, W; Ellsworth, BA; Nirschl, AA; McCann, PJ; Patel, M; Girotra, RN; Wu, G; Sher, PM; Morrison, EP; Biller, SA; Zahler, R; Deshpande, PP; Pullockaran, A; Hagan, DL; Morgan, N; Taylor, JR; Obermeier, MT; Humphreys, WG; Khanna, A; Discenza, L; Robertson, JG; Wang, A; Han, S; Wetterau, JR; Janovitz, EB; Flint, OP; Whaley, JM; Washburn, WN Discovery of Dapagliflozin: A Potent, Selective Renal Sodium-Dependent Glucose Cotransporter 2 (SGLT2) Inhibitor for the Treatment of Type 2 Diabetes. J Med Chem 51: 1145-9 (2008)